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The aim of the present study was to examine the prevalence and determine the
molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli
(ESBL-EC) causing bacteraemia in a Spanish Hospital over a 12-year period (2000 to
2011). As far as we know, this is the first study which has investigated and compared
the serotypes, phylogroups, clonotypes, virotypes, and PFGE profiles of ST131 and
non-ST131 clones of bacteraemia ESBL-EC isolates. Of the 2,427 E. coli bloodstream
isolates, 96 (4.0%) were positive for ESBL production: 40 for CTX-M-15, 36 for CTX-
M-14, eight for CTX-M-1, four for CTX-M-9, CTX-M-32, and SHV-12. The number
of ESBL-EC increased from 1.0% during 2000 to 2005 to 5.5% during 2006–2011
(P < 0.001). The 96 ESBL-EC isolates belonged to 36 different STs. The commonest
was ST131 (41 isolates), followed by ST58, ST354, ST393 and ST405 (four isolates
each). Most CTX-M-15 isolates (87.5%, 35/40) were ST131, whereas the 36 CTX-
M-14 isolates belonged to 23 different STs and only 3 (8.3%) of them were ST131.
The 35 ST131 CTX-M-15-producing isolates belonged to the H30Rx subclone and
29 of them showed the virotype A. A drastic change in ST131 virotypes happened in
2011 due to the emergence of the virotypes E (sat, papGII, cnf1, hlyA, and kpsMII-
K5) and F (sat, papGII, and kpsMII-K5) which displaced virotype A (afa/draBC, afa
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operon FM955459, sat, and kpsMII-K2). Although the 96 ESBL-EC isolates showed
21 O serogroups and 17 H flagellar antigens, 39 belonged to serotype O25b:H4
(ST131 isolates). The second most prevalent serotype (O15:H1) was found to be
associated with another important high-risk clone (ST393). In conclusion, the ST131
was the most frequent sequence type, being the H30Rx subclone responsible for
the significant increase of ESBL-EC isolates since 2006. Here, we report two new
virotypes (E and F) of the H30Rx subclone emerged in 2011. Future molecular studies
are needed to understand the dynamics of expansion of this successful high-risk
subclone in order to prevent its spread and establish the importance of the two
new virotypes.
Keywords: clonotypes, E. coli, ESBL, ExPEC, H30Rx subclone, ST131 clonal group
INTRODUCTION
Escherichia coli is the main cause of bloodstream infections (BSIs)
and in recent years there has been a very significant increase in the
number of infections caused by multidrug-resistant isolates, and
especially by extended-spectrum β-lactamase-producing E. coli
(ESBL-EC) (Tumbarello et al., 2010; de Kraker et al., 2013;
Vihta et al., 2018). ESBL production in E. coli has increased
due mainly to the spread of CTX-M enzymes. The high-
risk clones have played a very important role in the current
pandemic spread, especially the ST131 clone associated with
the CTX-M-15 enzyme (Nicolas-Chanoine et al., 2008; Chung
et al., 2012; Peirano et al., 2012; Adams-Sapper et al., 2013;
Banerjee et al., 2013; Colpan et al., 2013; Matsumura et al., 2013;
Johnson et al., 2017; Kallonen et al., 2017; Roer et al., 2017;
Mendis et al., 2018).
The majority of ST131 isolates belong to the O25b:H4
serotype, subclone H30, clonotype CH40-30 and clade C. The
H30Rx (clade C2) subset often carries blaCTX−M−15, whereas
H30R-M27 (clade C1-M27) subset is positive for blaCTX−M−27
and H30R-nM27 (clade C1-nM27) subset is often positive for
blaCTX−M−14. However, there are other two ST131 subclones
less frequently expanded: H22 (clonotype CH40-22, clade B)
and H41 (clonotype CH40-41, clade A). Isolates of subclone
H41 usually belong to serotype O16:H5 (Price et al., 2013;
Olesen et al., 2014; Peirano et al., 2014; Matsumura et al.,
2017a,b; Harris et al., 2018). Generally, clades A and B show
fluoroquinolone (FQ) susceptibility and rarely carry ESBL
plasmids, while most isolates of clade C are FQ-resistant. Clade
B evolved into clade C by acquisition of several prophages,
genomic islands, the fimH30 allele and mutations within gyrA
and parC genes, mainly during the late 1980s (Ben Zakour
et al., 2016; McNally et al., 2016; Stoesser et al., 2016; Pitout
and DeVinney, 2017). In addition, considering the content
of virulence genes, ST131 isolates can be classified into 12
virotypes (A to F) (Blanco et al., 2013; Dahbi et al., 2014;
Mora et al., 2014).
Currently, few data are available on molecular epidemiology
of bacteraemia caused by ST131 and non-ST131 clones of ESBL-
EC, especially in Europe (Rodríguez-Baño et al., 2012; Horner
et al., 2014; Day et al., 2016; Merino et al., 2016; Roer et al.,
2017). Thus, the aim of the present study was to examine
the prevalence and determine the molecular characteristics of
ESBL-EC causing bacteraemia in a Spanish Hospital over a 12-
year period (2000–2011).
MATERIALS AND METHODS
E. coli Bloodstream Isolates
The present study included 2,427 non-duplicate, clinically
relevant E. coli isolates recovered from blood of patients
at Hospital Universitario Lucus Augusti (HULA) (formely
Complejo Hospitalario Xeral-Calde) between January 2000
and December 2011. All available isolates from that time
period were analyzed. HULA is a university hospital with
740 beds, which serves an urban and rural population of
approximately 265,000 inhabitants in Lugo, Spain. Ethics
approval was not required according to national and
institutional guidelines.
Antibiotic Susceptibility Testing and
ESBL Typing
ESBL production was detected by the double disk synergy test
(Jarlier et al., 1988). The type of ESBL was established by
PCR and sequencing using the TEM-, SHV-, CTX-M-1, and
CTX-M-9 group-specific primers (Leflon-Guibout et al., 2004;
Blanco et al., 2009).
Phylogenetic Grouping, MLST, CH
Typing, and Identification of H30Rx
Subclone
The determination of the phylogenetic groups (A, B1, B2, C,
D, E, F) was carried out by the protocol of Clermont et al.
(2013). The sequence types (STs) were established following
the multilocus sequence typing (MLST) scheme of Achtman1
(Wirth et al., 2006). Clonotype identification was determined
by fumC and fimH (CH) sequencing (Weissman et al., 2012;
Tchesnokova et al., 2013). The H30Rx subclone was established
by PCR detection of a specific SNP (G723A) of ybbW gene
(Banerjee et al., 2013).
1http://enterobase.warwick.ac.uk/species/ecoli/allele_st_search
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O and H Typing
The serotyping was carried out using all available O (O1 to O181)
and H (H1 to H56) antisera (Guinée et al., 1981). Isolates that did
not react with any antisera were designated as ONT or HNT (NT,
non-typeable) and those non motile were denoted as HNM. The
O25b subtype was determined by PCR (Clermont et al., 2008).
Virulence Genotyping
Virulence genes were screened by PCR as documented previously
(Dahbi et al., 2014), using specific primers (Supplementary
Table S1). The virulence gene score was the number of
extraintestinal virulence-associated genes detected. Isolates were
defined presumptively as extraintestinal pathogenic E. coli
(ExPEC) (Johnson et al., 2015) if positive for ≥2 of 5 markers,
including papAH and/or papC, sfa/focDE, afa/draBC, kpsM II,
and iutA, and as uropathogenic E. coli (UPEC) (Spurbeck et al.,
2012) if positive for ≥3 of 4 markers, including chuA, fyuA, vat,
and yfcV. The virotypes A to F of the ST131 isolates was assigned
according to the scheme developed by Dahbi et al. (2014).
Pulsed Field Gel Electrophoresis (PFGE)
XbaI-PFGE profiles were determined as previously described
(Mora et al., 2009, 2010) and imported into BioNumerics
(Applied Maths, Sint-Martens-Latem, Belgium) and clustered
using the UPGMA algorithm and applying Dice coefficient
and 1% tolerance.
Statistical Analysis
All the P-values were calculated using the Fisher’s exact test,
except for the comparison of the means that was performed using
the test one-way ANOVA test. P-values <0.05 were considered
statistically significant.
RESULTS
Prevalence of ESBL-Producing E. coli
(ESBL-EC)
During 2000–2011, 2,427 E. coli bloodstream isolates were
analyzed, of which 96 (4.0%) exhibited ESBL production. The
number of ESBL-EC isolates increased from 1.0% (8/827) during
2000–2005 to 5.5% (88/1,600) during 2006–2011 (P < 0.001)
(Figure 1, Table 1, and Supplementary Table S2).
ESBL Enzymes
Of the 96 ESBL-EC isolates, 40 were positive for CTX-M-15, 36
for CTX-M-14, eight for CTX-M-1, and four for CTX-M-9, CTX-
M-32, and SHV-12 each (Figure 2 and Table 1).
Phylogenetic Groups
The commonest phylogenetic group was B2 (44 isolates),
followed by B1 (18 isolates), A and E (11 isolates from each), F
(six isolates), C (five isolates), and D (one isolate).
The majority of CTX-M-15-producing (87.5%, 35/40) isolates
belonged to phylogenetic group B2. In contrast, only five
(14%) of 36 CTX-M-14-producing isolates were assigned to this
phylogenetic group (P < 0.001) (Table 1).
Multilocus Sequence Types
The 96 ESBL-EC isolates belonged to 36 different STs (Table 1).
The commonest was ST131 (41 isolates), followed by ST58 (four
isolates), ST354 (four isolates), ST393 (four isolates), ST405 (four
isolates), and ST359 (three isolates). Most CTX-M-15 isolates
(87.5%, 35/40) were ST131, whereas the CTX-M-14 isolates
belonged to 23 different STs, none of which accounted for >12%
and only 3 (8.3%) of 36 isolates were ST131 (Table 1).
FIGURE 1 | Prevalence of extended-spectrum β-lactamase-producing E. coli (ESBL-EC) and ESBL-EC ST131 isolates. A total 2,427 E. coli bloodstream isolates
were analyzed, of which 96 (4.0%) exhibited ESBL production. A total of 41 ESBL-EC ST131 isolates were identified and 35 of them belonged to the H30Rx
subclone.
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TABLE 1 | Prevalence, serotypes, phylogenetic groups, STs, and clonotypes of extended-spectrum β-lactamase-producing E. coli (ESBL-EC) bloodstream isolates.






Serotypes, phylogenetic groups, sequence types, and clonotypes (number of
isolates)a
2000 142 0
2001 120 1 (0.8%) CTX-M-14 (1) O2:H5-B2-ST352-CH96-9 (1)
2002 93 0
2003 90 1 (1.1%) CTX-M-14 (1) O15:H1-E-ST393-CH106-54 (1)
2004 199 3 (1.5%) CTX-M-14 (1) O105:H21-B1-ST359-CH41-35 (1)
CTX-M-9 (1) O144:HNM-B1-ST602-CH19-86 (1)
CTX-M-1 (1) O15:HNM-E-ST362-CH100-96 (1)
2005 183 3 (1.6%) CTX-M-32 (2) O25a:H25-B1-ST359-CH41-55 (1); O25a:HNM-F-ST648-CH4-58 (1)
CTX-M-14 (1) O8:HNT-A-ST48-CH11-0 (1)
2006 190 8 (4.2%) CTX-M-15 (2) O25b:H4-B2-ST131-CH40-30 (2)
CTX-M-14 (5) O8:H7-B1-ST1642-CH4-31 (1); O23:HNM-B1-ST453-CH6-31 (1);
O25b:H4-B2-ST131-CH40-negative (1); O102:H6-E-ST405-CH37-27 (1);
O153:H34-F-ST354-CH88-58 (1)
CTX-M-32 (1) O2:H4-B2-ST95-CH38-27 (1)
2007 231 8 (3.5%) CTX-M-15 (5) O25b:H4-B2-ST131-CH40-30 (5)
CTX-M-14 (1) ONT:H4-A-NEW STb-CH11-25 (1)
CTX-M-9 (1) ONT:H10-B1-ST711-CH6-289 (1)
CTX-M-1 (1) O8:HNT-B1-ST345-CH4-31 (1)
2008 276 15 (5.4%) CTX-M-15 (6) O20:H9-C-ST410-CH4-24 (1); O20:H30-B1-ST156-CH29-38 (1);
O25b:H4-B2-ST131-CH40-30 (4)
CTX-M-14 (7) ONT:HNM-B1-ST58-CH4-32 (1); ONT:H25-B1-ST58-CH4-32 (1);
ONT:HNM-C-ST23-CH4-35 (1); ONT:H51-B1-ST359-CH41-35 (1);
ONT:H5-B2-ST131-CH40-41 (1); O1:HNM-F-ST354-CH88-58 (1);
ONT:H18-D-ST69-CH35-27 (1)
CTX-M-9 (1) O25b:H4-B2-ST131-CH40-22 (1)
CTX-M-1 (1) ONT:H16-B1-ST2602-CH95-38 (1)
2009 289 14 (4.8%) CTX-M-15 (10) O25b:H4-B2-ST131-CH40-30 (10)
CTX-M-14 (3) O15:H1-E-ST393-CH106-54 (3)
CTX-M-32 (1) O101:H10-A-ST10-CH11-54 (1)
2010 301 17 (5.6%) CTX-M-15 (6) O25b:H4-B2-ST131-CH40-30 (3); O8:H6-E-ST405-CH37-27 (1);
O130:H6-E-ST405-CH37-27 (1); ONT:H6-E-ST405-CH37-27 (1)
CTX-M-14 (8) O7:H4-A-ST93-CH11-31 (1); O9:H4-A-ST615-CH7-34 (1);
O101:H10-A-ST617-CH11-negative (1); O153:H19-C-ST58-CH4-25 (1);
O91:H28-B1-ST1196-CH6-31 (1); O2:HNM-B2-ST141-CH52-14 (1);
O16:H5-B2-ST131-CH40-41 (1); O77:H18-E-ST106-CH35-47 (1)
CTX-M-9 (1) O25b:H4-B2-ST131-CH40-22 (1)
SHV-12 (2) O68:H21-B1-ST602-CH19-86 (1); ONT:HNM-A-ST10-CH11-54 (1)
2011 313 26 (8.3%) CTX-M-15 (11) O25b:H4-B2-ST131-CH40-30 (11)
CTX-M-14 (8) O7:H4-A-ST93-CH11-31 (1); O8:H4-C-ST88-CH4-39 (1); O9:H4-A-ST609-CH7-0 (1);
O11:H9-C-ST1615-CH263-32 (1); O8:H7-B1-ST1642-CH4-31 (1);
O23:H28-B1-ST156-CH29-38 (1); O153:H34-F-ST354-CH88-58 (1);
ONT:H34-F-ST354-CH88-58 (1)
CTX-M-1 (5) ONT:HNM-A-ST1630- CH11-400 (1); O9:H4-A-ST1421-CH7-54 (1);
O54:H21-B1-ST58-CH4-0 (1); ONT:H25-B1-ST641-CH6-479 (1); O153:H15-E-
ST973-CH187-27 (1)
SHV-12 (2) O25b:H4-B2-ST131-CH40-22 (1); O2:HNM-F-ST648-CH4-58 (1)
Total 2.427 96 (4.0%)
aThe ST131 isolates are highlighted in bold. bNew ST: adk-10, fumC-11, gyrB-4, icD-8, mdh-492, purA-8 and recA-2.
Clonotypes
CH typing identified 40 clonotypes, with CH40-30
being the most prevalent, which was present in 35
ST131 CTX-M-15-producing isolates. Other prevalent
clonotypes were: CH41-35 (three ST359 isolates), CH40-
22 (three ST131 isolates), CH106-54 (four ST393 isolates),
CH37-27 (four ST405 isolates), and CH88-58 (four ST354
isolates) (Table 1).
Serotypes
The 96 ESBL-EC isolates belonged to 21 O serogroups and
expressed 17 H flagellar antigens. However, 39 ST131 isolates
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FIGURE 2 | Distribution of extended-spectrum β-lactamase (ESBL) enzymes. Of the 96 ESBL-EC bloodstream isolates, 40 were positive for CTX-M-15, 36 for
CTX-M-14, eight for CTX-M-1, and four for CTX-M-9, CTX-M-32, and SHV-12 each.
belonged to serotype O25b:H4. Other prevalent serotypes were:
O15:H1 (four ST393 isolates), O9:H4 (three CC46 isolates),
O7:H4 (two ST93 isolates), O8:H7 (two ST1642 isolates),
O101:H10 (two CC10 isolates), and O153:H34 (two ST354
isolates) (Table 1).
Virulence Genes
The ST131 isolates showed a higher virulence score (range 11 to
21; mean 13.49) compared with the non-ST131 isolates (range 1
to 18; mean 8.31) (P < 0.001).
Fourteen virulence genes (afa/draBC, afaFM955459, yfcV, sat,
cnf1, iucD, iutA, fyuA, chuA, kpsM II, kpsM II-K2, malX, usp, and
ompT) were significantly associated with ST131 isolates, whereas
only five virulence genes (fimAvMT78, hlyF, vat, iroN, cvaC, iss,
and traT) were significantly associated with non-ST131 isolates.
Of the 96 ESBL-EC isolates, 65.6% were classified as ExPEC
and 44.8% classified as UPEC. The prevalence of ExPEC (97.6
vs. 41.8%) (P < 0.001) and UPEC (90.2 vs. 10.9%) (P < 0.001)
status were higher within ST131 isolates than within non-ST131
isolates (Table 2).
H30Rx Subclone and Virotypes of ST131
Isolates
The 35 ST131 O25b:H4 CTX-M-15-producing isolates belonged
to the H30Rx subclone. Twenty-six of the 35 H30Rx isolates
showed the virotype A, four isolates the virotype E and five
isolates the virotype F. In contrast, the three isolates of H22
subclone showed the virotypes D2 (one isolate) and D4 (two
isolates). Besides, one of the two isolates belonging to H41
subclone showed the virotype C3, while the other was non-
typeable (NT).
In 2011, there was a very drastic change in the virotypes,
due to the emergence of the virotypes E (sat, papGII, cnf1, hlyA,
and kpsMII-K5) and F (sat, papGII, and kpsMII-K5) which have
displaced the virotype A (afa/draBC, afa operon FM955459, sat,
and kpsMII-K2). Thus 8 (66.7%) of the 12 ST131 isolates obtained
in 2011 belonged to virotypes E and F vs. 1 (3.4%) of 29 ST131
isolates from 2006 to 2010 (P < 0.001). By contrast, while in
the first period 23 (79.3%) of 29 ST131 isolates belonged to
virotype A in the last year represented only 3 (25%) of 12 isolates
(P = 0.002) (Figure 3).
Macrorestriction Profiles by PFGE
Supplementary Figures S1, S2 show a dendrogram with the
XbaI macrorestriction profiles of the ST131 and non-ST131
which showed a similarity of 61.3 and 50.2%, respectively.
A high genetic diversity was detected among the 40 ST131
isolates, showing 31 different PFGE profiles. However, the isolates
remained distributed within three virotype-specific clusters of
75% (four virotype E isolates), 84.2% (25 virotype A isolates)
and 94.6% identity (five virotype F isolates). As expected, the
55 non-ST131 isolates showed even more heterogeneity, with 55
different profiles. However, the majority of isolates belonging to
the same STs, clonotypes and O:H serotypes grouped together
in the dendrogram.
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TABLE 2 | Virulence genes in ST131 and non-ST131 bloodstream isolates.









fimH D-mannose-specific adhesin, type 1 fimbriae 94 (97.9%) 40 (97.6%) 54 (98.1%)
fimAvMT78 Fim A variant MT78 of type 1 fimbriae 10 (10.4%) 0 10 (18.2%) 0.003
papAH P fimbriae operon. Major structural subunit 21 (21.9%) 10 (24.4%) 11 (20.0%)
papC P fimbriae operon. Pilus assembly 21 (21.9%) 10 (24.4%) 11 (20.0%)
papEF P fimbriae operon. Minor tip pilins. 22 (22.9%) 10 (24.4%) 12 (21.8%)
papG I P fimbriae operon. Allele I of papG gene 0 0 0
papG II P fimbriae operon. Allele II of papG gene 16 (16.7%) 9 (22.0%) 7 (12.7%)
papG III P fimbriae operon. Allele III of papG gene 2 (2.1%) 1 (2.4%) 1 (1.8%)
papG IV P fimbriae operon. Allele IV of papG gene 0 0 0
sfa/focDE Sfa (S fimbriae) and foc (F1C fimbriae) operons 1 (1.0%) 0 1 (1.8%)
afa/draBC Dr antigen-specific adhesin operons 27 (28.1%) 27 (65.9%) 0 < 0.001
afaFM955459 Operon afa specific for clone O25b-ST131 26 (27.1%) 26 (63.4%) 0 < 0.001
yfcV Putative chaperone-usher fimbria 49 (51.0%) 37 (90.2%) 12 (21.8%) < 0.001
Toxins
sat Secreted autotransporter toxin 45 (46.9%) 37 (90.2%) 8 (14.5%) < 0.001
cnf1 Cytotoxic necrotizing factor 1 4 (4.2%) 4 (9.8%) 0 0.030
hlyA α-hemolysin 5 (5.2%) 4 (9.8%) 1 (1.8%)
hlyF Hemolysin F 25 (26.0%) 4 (9.8%) 21 (38.2%) 0.001
cdtB Cytolethal distending toxin 1 (1.0%) 1 (2.4%) 0
tsh Tsh (temperature-sensitive hemagglutinin) serine
protease
10 (10.4%) 2 (4.9%) 8 (14.5%)
vat Vacuolating autotransporter toxin. Serine protease 6 (6.3%) 0 6 (10.9%) 0.031
Iron uptake
iucD Ferric aerobactin receptor 81 (84.4%) 41 (100%) 40 (72.7%) < 0.001
iutA Ferric aerobactin receptor 81 (84.4%) 41 (100%) 40 (72.7%) < 0.001
iroN Catecholate (salmochelin) siderophore receptor 21 (21.9%) 3 (7.3%) 18 (32.7%) 0.002
fyuA Yersinia siderophore receptor 65 (67.7%) 41 (100%) 24 (43.6%) < 0.001
chuA Heme binding outer membrane 62 (64.6%) 41 (100%) 21 (38.2%) < 0.001
Capsule
kpsM II Group II capsule 60 (62.5%) 40 (97.6%) 20 (36.4%) < 0.001
kpsM II-K2 K2 variant of group II capsule 27 (28.1%) 27 (65.9%) 0 < 0.001
kpsM II-K5 K5 variant of group II capsule 29 (30.2%) 11 (26.8%) 18 (32.7%)
neuC-K1 K1 antigen 4 (4.2%) 2 (4.9%) 2 (3.6%)
kpsM III: Group III capsule 3 (3.1%) 0 3 (5.5%)
Miscellaneous
cvaC ColV (microcin V) 17 (17.7%) 3 (7.3%) 14 (25.5%) 0.018
iss Increased serum survival (OMP) 19 (19.8%) 3 (7.3%) 16 (29.1%) 0.007
traT Serum resistance-associated (OMP) 56 (58.3%) 18 (43.9%) 38 (69.1%) 0.012
ibeA Invasion of brain endothelium 9 (9.4%) 3 (7.3%) 6 (10.9%)
malX Pathogenicity-associated island marker (PAI) 55 (57.3%) 41 (100%) 14 (25.5%) < 0.001
usp Uropathogenic-specific protein (bacteriocin) 48 (50.0%) 41 (100%) 7 (12.7%) < 0.001
ompT Outer membrane protein (protease) T 70 (72.9%) 41 (100%) 29 (52.7%) < 0.001
ExPEC status If positive for ≥2 of 5 markers, including papAH and/or
papC, sfa/focDE, afa/draBC, kpsM II and iutA
63 (65.6%) 40 (97.6%) 23 (41.8%) < 0.001
UPEC status If positive for ≥3 of 4 markers, including chuA, fyuA, vat
and yfcV.
43 (44.8%) 37 (90.2%) 6 (10.9%) < 0.001
aP-values were calculated using the Fisher’s exact test and are shown where P < 0.05. Significant differences are indicate in bold.
DISCUSSION
The management of BSIs due to E. coli has been complicated
due to antimicrobial resistance emergence, especially since 2000.
A low proportion of the bacteraemia E. coli isolates recovered in
our hospital between 1989 and 1992 were resistant to extended-
spectrum cephalosporins (ESC) (0.5%) and fluoroquinolones
(FQs) (1%), and none of the 213 E. coli isolates was multidrug
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FIGURE 3 | Distribution of subclones and virotypes of extended-spectrum β-lactamase-producing E. coli (ESBL-EC) ST131 bloodstream isolates. A drastic change
in ST131 virotypes happened in 2011 due to the emergence of the virotypes E and F, which displaced virotype A.
resistant (MDR). However, a significant number turned out to
be resistant (ESC 8%, FQs 31%, and MDR 16%) within 614
bacteraemia E. coli isolates obtained between 2010 and 2011
(unpublished data).
Escherichia coli BSIs are increasing in Europe and worldwide
mainly due to the increased resistance to antibiotics, and
especially to the expansion of high-risk clones such as ST131
(Tumbarello et al., 2010; de Kraker et al., 2013; Vihta et al.,
2018). Since 2006, it is evident that the prevalence of ESBL-
EC has raised in our hospital. This increase has been due to
the spread of the multidrug-resistant H30Rx subclone associated
with the production of CTX-M-15. Thus, the number of ESBL-
EC isolates increased from 1.0% during 2000–2005 to 5.5%
during 2006–2011. While during the first period 0% of the
ESBL-EC isolates belonged to H30Rx subclone, in the second
period this subclone represented 39.8%. A similar situation has
been reported in other hospitals worldwide. Specifically, in a
centralized Canadian region (Calgary), Peirano et al. (2012)
investigated the prevalence and molecular characteristics of
ESBL-EC bloodstream isolates obtained from the year 2000 to
2010 and found that these isolates increased significantly in the
last years of the study (2% during 2000–2006 vs. 8% during
2007–2010). ST131 was first described in 2001, and its prevalence
remained stable until 2006. However, since 2007, the prevalence
of ST131 isolates increased significantly. Like in our study, most
isolates from Canada produced either CTX-M-15 or CTX-M-14
(Peirano et al., 2012).
In the present study, while most of the 40 CTX-M-15-
producing isolates belonged to ST131, the 36 CTX-M-14 positive
isolates were distributed within 23 different STs. Similar results
were observed by Merino et al. (2016) who reported a prevalence
of 9.2% (39/425) of ESBL-EC among isolates causing bacteraemia
of urinary origin in eight Spanish hospitals during 2010 and
2011. Of the 39 ESBL-EC isolates, 21 produced CTX-M-15 and
11 CTX-M-14. Fifteen STs were identified, but as in our study,
the ST131 H30Rx subclone was predominant among CTX-M-
15 isolates (20 of 21 isolates). Another seven STs (ST69, ST156,
ST359, ST405, ST410, ST453, and ST609) reported by Merino
et al. (2016) were also identified in the present study. However,
the phylogroup distribution of our study differed from the one
showed by Merino et al. (2016): A (11.5 vs. 7.7%), B1 (18.8 vs.
23.1%), B2 (45.8 vs. 53.8%), C (5.2 vs. 5.1%), D (1.0 vs. 10.3%), E
(11.5 vs. 0%), and F (6.3 vs. 0%).
In our investigation, the CH typing identified 40 clonotypes,
subdiving ST131 isolates in three subclones: CH40-30 (35 H30-
Rx isolates of subclade C2), CH40-22 (three H22 isolates
of clade B), and CH40-41 (two H41 isolates of clade A).
Recently, Roer et al. (2018) presented a new Web tool for
CH typing. To determine the resolution of it, 243 E. coli
isolates were analyzed. Those isolates were resistant to third-
generation cephalosporins and obtained from Danish patients
with BSIs. A total of 48 different STs were identified, with
ST131 the most common (50.2% of isolates; 95 CH40-30, 14
CH40-27, 11 CH40-41, one CH40-22, and one CH40-35). In
addition to ST131, other 15 STs (ST23, ST58, ST69, ST88,
ST93, ST95, ST141, ST345, ST354, ST393, ST405, ST410, ST453,
ST617, and ST648) were identified in both studies. Thus, 72.9%
of the Spanish isolates presented the same STs as 72.8% of
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the Danish isolates. Besides, the majority of the Spanish and
Danish bloodstream isolates of the same ST displayed as well
the same clonotype. Also, many of the STs found among our
isolates were identified within the ESBL-EC isolates collected
from BSIs in Japan (ST10, ST23, ST58, ST69, ST93, ST95,
ST131, ST156, ST354, ST362, ST393, ST405, ST602, and ST648)
(Matsumura et al., 2013), in Korea (ST10, ST69, ST95, ST131,
ST354, ST393, ST405, ST410, ST453, ST617, ST648, and ST1642)
(Kang et al., 2013), and in China (ST10, ST23, ST58, ST69, ST95,
ST131, ST393, ST405, ST410, ST602, ST617, ST648, and ST1642)
(Wang et al., 2016).
In Japan and other Asian countries, the CTX-M-27-
producing C1/H30R-M27 and CTX-M-14-producing C1/H30R-
nM27 subclades are more frequently isolated than the CTX-M-
15-producing C2/H30Rx subclade (Matsumura et al., 2017b). We
have not detected these two subclades within the collection of
the study reported here (2000-2011). However, the epidemiologic
situation seems to be changing in Spain since we have detected
the subclade C1/H30R-M27 (five cases) within 92 ESBL-EC
obtained from patients with urinary tract infections (84 cases)
and other extraintestinal infections of our hospital in 2015,
being the most frequent after the C2/H30Rx subclade (27 cases)
(Flament-Simon et al., 2019).
The ST131 bloodstream isolates showed a higher virulence
score than non-ST131 isolates. Furthermore, the prevalence
of the ExPEC and UPEC status was also higher among the
ST131 isolates than in the non-ST131 isolates, supporting the
idea of a greater virulence potential of ST131, confirming the
findings of previous studies (Blanco et al., 2011, 2013; Dahbi
et al., 2014; Merino et al., 2016). However, the success of ST131
isolates cannot be explained exclusively by its high number of
virulence genes. ST131 isolates are carriers of both virulence and
resistance genes, which is very rare in classical extraintestinal
pathogenic E. coli isolates (Nicolas-Chanoine et al., 2014). In
addition, most ESBL-producing ST131 isolates are resistant to
both extended-spectrum cephalosporins and fluoroquinolones
(Colpan et al., 2013; Johnson et al., 2013). Diverse fitness cost
associated with high-level resistance to fluoroquinolones was
reported to contribute to the selection of the international
clones of methicillin-resistant Staphylococcus aureus, Clostridium
difficile ESBL-producing Klebsiella pneumoniae and E. coli
(Fuzi et al., 2017). It is also important to highlight that the
major reservoir of human extraintestinal pathogenic E. coli
is the human digestive tract and that ST131 is the most
competitive of the phylogenetic group B2 clones known
to colonize the human digestive tract (Blanc et al., 2014;
Nicolas-Chanoine et al., 2014). Recently, McNally et al.
(2019) after analyzing the genome of 1,094 systematically
sampled bacteremia ST131 isolates from the British Society
for Antimicrobial Chemotherapy (BSAC) collection, found
that clade C had accumulated a significantly elevated allelic
diversity, particularly enriched for genes involved in anaerobic
metabolism as well as other loci important for colonization of the
human host by ExPEC.
In the present study, most of the isolates ST131 showed the
virotype A. The international pulsotype L, which was responsible
for the significant increase in BSIs in Calgary since 2007, also
belonged to the virotype A and subclone H30Rx (Peirano et al.,
2014). However, in many countries, the virotype C is the most
frequent among ESBL-EC isolates belonging to H30Rx subclone
(Olesen et al., 2014; Peirano et al., 2014). The isolates of virotypes
E and F obtained during the last year (2011) of our study may
possibly represent new sublineages of the ST131 clonal group.
A high genetic diversity was detected by PFGE. However, the
ST131 isolates grouped in three specific clusters of virotypes A,
E, and F suggesting a clonal basis for the virotypes (Blanco et al.,
2013). In future studies it would be very interesting to determine
the whole genome sequence of the ST131 isolates belonging to
virotypes A, E and F to know if they really belong to different
branches within the H30Rx C2 subclade.
In the present study we have not detected any carbapenem-
resistant E. coli, but O25b:H4-ST131- H30-Rx isolates of virotype
E and co-producing CTX-M-15 and OXA-48 were recently
reported in another Spanish hospital (HUCA, Oviedo) near our
region (de Toro et al., 2017).
The present study has certain limitations such as it was
performed in a single hospital, non-ESBL ST131 isolates were not
included, lack of whole genome sequencing (WGS) analysis or
the fact that the last isolates were obtained during 2011.
CONCLUSION
ST131 was the sequence type most frequently detected; moreover,
the H30Rx subclone was responsible for the significant increase
of ESBL-EC bloodstream isolates since 2006. In the year 2011
two new virotypes (E and F) of H30Rx subclone have emerged.
Future molecular studies are needed to understand the dynamics
of expansion of this successful high-risk subclone in order
to prevent its spread and establish the importance of the
two new virotypes.
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